(Q36920653)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Safety considerations with bisphosphonates for the treatment of osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

William Strampel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Ronald Emkey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

755-763

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00002018-200730090-00003

4 January 2020

exact match

0 references

cites work

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730090-00003

Pathogenesis and natural history of osteonecrosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730090-00003

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200730090-00003

Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis

21 January 2018

1 reference

12 December 2020

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

1 reference

12 December 2020

Early discontinuation of treatment for osteoporosis

1 reference

12 December 2020

Alendronate and naproxen are synergistic for development of gastric ulcers

1 reference

12 December 2020

Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis

1 reference

12 December 2020

Esophagitis associated with the use of alendronate

1 reference

12 December 2020

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Renal failure associated with intravenous diphosphonates

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

12 December 2020

Adverse effects of bisphosphonates. A comparative review

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Osteoporosis: part I. Evaluation and assessment

1 reference

12 December 2020

Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease

1 reference

12 December 2020

Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation.

1 reference

12 December 2020

Costs of acid-related disorders to a health maintenance organization

1 reference

12 December 2020

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

1 reference

12 December 2020

Bone safety of long-term bisphosphonate treatment

1 reference

12 December 2020

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

1 reference

12 December 2020

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

12 December 2020

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

1 reference

12 December 2020

Better osteoporosis management a priority: impact predicted to soar with aging population.

1 reference

12 December 2020

Oesophageal stricture associated with alendronic acid

1 reference

12 December 2020

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

12 December 2020

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study

1 reference

12 December 2020

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Tolerability and compliance with risedronate in clinical practice

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Decimal point--osteoporosis therapy at the 10-year mark

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

Bisphosphonates: clinical experience

1 reference

12 December 2020

Renal Failure with the Use of Zoledronic Acid

1 reference

12 December 2020

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

12 December 2020

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.2165/00002018-200730090-00003

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17722968%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 January 2020

1052609562

0 references

1 reference